Skip to main content
Xiao Xu, MD, Pathology, Overland Park, KS

Xiao Meng Xu MD

Anatomic Pathology, Clinical Pathology


Physician

Join to View Full Profile
  • 7301 College BlvdSte. 110Overland Park, KS 66210

  • Phone+1 913-341-6297

  • Fax+1 913-341-6299

Are you Dr. Xu?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Xiao Xu, MD is a board certified pathologist in Overland Park, Kansas. She is currently licensed to practice medicine in Kansas, Arizona, and Texas.

Education & Training

  • Rutgers Health/Robert Wood Johnson Medical School
    Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Pathology-Anatomic and Clinical, 1995 - 1998
  • Shanghai Medical University
    Shanghai Medical UniversityClass of 1987

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2019 - 2026
  • CA State Medical License
    CA State Medical License 2017 - 2026
  • TX State Medical License
    TX State Medical License 2019 - 2021
  • KS State Medical License
    KS State Medical License 2009 - 2020
  • MO State Medical License
    MO State Medical License 2010 - 2020
  • Anatomic Pathology & Clinical Pathology
    American Board of Pathology Anatomic Pathology & Clinical Pathology

Publications & Presentations

PubMed

Press Mentions

  • Effects of ATP9A on Extracellular Vesicle Release and Exosomal Lipid Composition
    Effects of ATP9A on Extracellular Vesicle Release and Exosomal Lipid CompositionOctober 29th, 2020
  • Severity of Early Allograft Dysfunction Following Donation After Circulatory Death Liver Transplantation: A Multicentre Study
    Severity of Early Allograft Dysfunction Following Donation After Circulatory Death Liver Transplantation: A Multicentre StudyOctober 14th, 2019
  • ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
    ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease DrugJune 14th, 2017